Stephan Seitz

Franz Josef Strauss Allee 11
Regensburg, BY 93053, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 62 publications

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.

Journal: NPJ breast cancer

Published: November 29, 2025

Locoregional Breast Cancer Recurrences After Ablatio Mammae and Primary Reconstruction.

Locoregional Breast Cancer Recurrences After Ablatio Mammae and Primary Reconstruction.

Journal: Journal of clinical medicine

Published: November 11, 2025

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.

Journal: Breast cancer research and treatment

Published: October 24, 2025

Chemotherapy in elderly patients with early breast cancer: a systematic review.

Chemotherapy in elderly patients with early breast cancer: a systematic review.

Journal: Archives of gynecology and obstetrics

Published: May 21, 2025

Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients.

Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients.

Journal: BMC medicine

Published: May 02, 2025

Treatment Regimens and Response Rates in Early TNBC: A Review of Real-World Practice in the Second Decade of the 21st Century.

Treatment Regimens and Response Rates in Early TNBC: A Review of Real-World Practice in the Second Decade of the 21st Century.

Journal: The breast journal

Published: March 18, 2025

Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy.

Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy.

Journal: Cancer cell international

Published: January 14, 2025

Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus.

Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus.

Journal: Geburtshilfe und Frauenheilkunde

Published: December 19, 2024

Histologic Characterization of Tumor-Adjacent Mammary Adipose Tissue in Normal-Weight and Overweight/Obese Patients with Triple-Negative Breast Cancer.

Histologic Characterization of Tumor-Adjacent Mammary Adipose Tissue in Normal-Weight and Overweight/Obese Patients with Triple-Negative Breast Cancer.

Journal: Cancers

Published: September 03, 2024

HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice.

HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice.

Journal: International journal of molecular sciences

Published: May 27, 2024

Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients.

Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients.

Journal: Molecular oncology

Published: January 30, 2024

Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative -specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy.

Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative -specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy.

Journal: Frontiers in immunology

Published: December 13, 2023

Showing 1-12 of 62

Last Updated: 09/26/2026